{
    "studies": [
        {
            "identificationModule": {
                "nctId": "NCT01175837",
                "officialTitle": "Short-Term Fasting Prior to Systemic Chemotherapy: A Pilot Feasibility Study"
            },
            "eligibilityModule": {
                "inclusionCriteria": "* Histologically confirmed malignancy\n* Scheduled to undergo 4 or more cycles of chemotherapy (with or without past chemotherapy treatment); NOTE: Acceptable chemotherapy regimens are those that have all drugs infused on the first day of the chemotherapy cycle over a period =\\< 8 hours; EXCEPTION: Continuous 5-FU-containing regimens (such as FOLFOX6 and FOLFIRI) are allowed as both the 5-FU bolus as well as the oxaliplatin and irinotecan administration is completed on day 1 of chemotherapy\n* Life expectancy of \\>= 168 days (6 months)\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Body mass index (BMI) \\> 21 kg/m\\^2\n* Weight loss \\< 5% of body weight in the last 168 days (6 months)\n* Adequate renal function (serum creatinine \\< 1.5 X UNL \\[upper normal limit\\] or creatinine clearance \\> 50 ml/min)\n* Negative pregnancy test done =\\< 7 days prior to registration, for women of childbearing potential only\n* Provide informed consent\n* Ability to complete patient booklet by themselves or with assistance\n* Ability and willingness to undergo \\>= 24-hour fast prior to chemotherapy\n* Willingness to be treated at Mayo Clinic Rochester and be available for follow-up\n* Patient willing to provide blood samples for correlative research purposes\n* Must have minimum age of 18 Years",
                "exclusionCriteria": "* Any of the following:\n\n  * Pregnant women;\n  * Nursing women;\n  * Men or women of childbearing potential who are unwilling to employ adequate contraception throughout the study period\n* Diabetes mellitus undergoing therapy with insulin or oral agents\n* History of low serum glucose (hypoglycemia) or insulinoma\n* History of syncope with calorie restriction in the past or other medical comorbidity, which would make fasting potentially dangerous\n* On daily medication that may not be safely taken without food; NOTE: Any non-essential medications and herbal/vitamin supplements should be held to minimize stomach upset during fasting; vitamin C use is discouraged\n* Active gastric or duodenal peptic ulcer disease\n* History of significant cardiac disease, particularly uncompensated congestive heart failure New York Heart Association (NYHA) grade 2 or more or left ventricular ejection fraction (LVEF) \\< 40% on any prior assessment; NOTE: Assessment of LVEF prior to therapy is not required in the absence of other clinical indicators of heart disease\n* Recent history (\\< 6 months) of cerebrovascular accident or transient ischemic attacks\n* History of gout or elevated uric acid level\n* Psychiatric conditions that preclude adherence to study protocol\n* Serious intercurrent infections or nonmalignant medical illnesses that are uncontrolled or whose control may potentially be jeopardized by the complications of fasting\n* Patients receiving parenteral nutrition\n* Receiving steroids (except dexamethasone given for nausea prevention before chemotherapy)\n* Patients receiving taxotere-containing chemotherapy regimens requiring pre-treatment steroid administration\n* Receiving concomitant treatment with insulin-like growth factor (IGF)-receptor blockers or monoclonal antibodies targeting the IGF ligands\n* Any of the following (prior to registration):\n\n  * =\\< 7 days from the time of a minor surgery;\n  * =\\< 21 days from the time of major surgery;\n  * =\\< 21 days from the time of radiation therapy\n* Currently enrolled in a concomitant clinical trial"
            }
        }
   ]
}